Linkage studies indicate that chromosome 22q contains a locus, or loci, for schizophrenia (SZ) and bipolar disorder (BPD). Furthermore, the congenital disorder velo cardio facial syndrome (VCFS), which is usually caused by a 22q11 microdeletion, is associated with an increased prevalence of psychiatric disease, including SZ and BPD. One plausible candidate gene that maps to 22q11, in a region deleted in the most common form of VCFS, is SNAP29, a member of the SNAP-25 family of SNARE proteins. To search for possible functional mutations in SNAP29 that could be analyzed as candidates for 22q11-linked psychiatric problems, exons, intron-exon junctions and the promoter region were screened. No coding variants were found, although a silent mutation at codon 6 and three single nucleotide polymorphisms (SNPs) were identified in the 5Ј untranslated and promoter regions. One SNP, an A→G transition 849 nucleotides upstream of the transcription start site, showed a moderately significant difference in the distribution of alleles and genotypes in patients with SZ compared with controls (allele frequency: 2 = 5.57, 1 df, P = 0.018; genotype: 2 = 9.49, 2 df, P = 0.009; odds ratio = 1.59, 95% Cl = 1.08-2.34). No significant difference was found in patients with BPD. Although the functional significance of this mutation is not known, the tetranucleotide core sequence of the ets and IK2 families of transcription factors is altered as a result of the SNP. These data suggest that a mutation in the SNAP29 gene promoter region, or a mutation in linkage disequilibrium with the promoter SNP, may be involved in the pathogenesis of chromosome 22-linked SZ. Molecular Psychiatry (2001) 6, 193-201. 
Introduction
Genes involved in synaptic vesicle function are plausible candidates for schizophrenia (SZ) and bipolar disorder (BPD) vulnerability. Synaptic vesicle docking and the exocytosis-endocytosis cycle are mediated by a variety of factors present on synaptic vesicles and the presynaptic membrane. The core complex is a tripartate structure composed of members of the synaptobrevin (also known as VAMP), syntaxin, and SNAP-25 (synaptosome associated protein-25 kD) families. [1] [2] [3] [4] [5] The notion that abnormal regulation of vesicle function may underlie some mental disorders is based on a number of observations. First, vesicle exocytosis is regulated by calcium influx and phosphoinositides, both of which are potential targets for some of the drugs used to treat BPD. Second, depletion of vesicle catecholamines by reserpine may cause depression, especially in patients with underlying depressive disorder, 6, 7 suggesting the possibility that some individuals have an intrinsic impairment in vesicle function Fourth, deletion of SNAP25 is responsible for the behavioral alterations found in coloboma mice, an animal model of ADHD. [9] [10] [11] The clinical features of ADHD overlap with the symptoms of mania and hypomania. Finally, a decrease in SNAP-25 and synaptophysin proteins has been found in the brains of schizophrenics. [12] [13] [14] [15] [16] Interestingly, a number of genes encoding SNARE and vesicle proteins map to regions of the genome that are suspected to harbor BPD and SZ susceptibility genes. SNAP29, RAB36, synapsin III and synaptogyrin 1 map to chromosome 22q11-13, synapsin I and synaptophysin map to Xp11, SYBL1 maps to Xq28, and syntaxin 7 maps to chromosome 6q21. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] SYNJ1, which encodes a phosphatase that is enriched in synaptic termini and which is involved in vesicle endocytosis, maps to 21q22, which also contains a BPD susceptibility gene. 22, [29] [30] [31] Based on these observations, we, and others, have been analyzing genes involved in synaptic vesicle function found in regions of the genome suspected to harbor BPD and SZ susceptibility genes. Recently, for example, we identified a polymorphism in a conserved intron regulatory domain (a polypyrimidine tract) in SYBL1, a synaptobrevin analog on Xq28, that may be associated with BPD in males. 32 A recent analysis of the synapsin III gene in schizophrenics did not reveal any potential disease causing mutations. 33 The SNAP25 analog SNAP29 maps to a region on chromosome 22q11 that is deleted in the majority of patients with VCFS. 25, 34 VCFS is a haploinsufficiency disorder associated with a variety of physical traits including a typical facial appearance, cleft palate and cardiac defects, as well as psychiatric problems and learning disability. 20, [35] [36] [37] [38] [39] [40] [41] An increased prevalence of SZ and BPD, in particular an ultra-ultra rapid cycling variety, have both been reported in VCFS patients [38] [39] [40] [41] and approximately 1-2% of chronic schizophrenics are found to contain 22q11 deletions. 20, 41 Linkage studies have also provided some support for the presence of a BPD and/or SZ locus on 22q11 in the general population. [17] [18] [19] [42] [43] [44] Recently, a marker on 22q11 that maps approximately 5 megabases (mb) telomeric to the VCFS deleted region was found to be linked to the antisaccadic ocular motor performance and P50 auditory sensory gating abnormalities found in schizophrenics and non-schizophrenic family members. 45 Also, linkage disequilibrium mapping using SNPs provided support for a SZ locus on 22q11 within the VCFS deleted region. 46 The relationship between these findings with the psychiatric manifestations of VCFS is not clear at this time. Most of the mapping studies conducted on SZ and BPD families point to a region telomeric to the VCFS deletion. However, because of the imprecision of the non-parametric linkage methods used in the mapping studies, it is very possible that the same gene is involved in the development of the psychiatric problems in VCFS and 22q11-linked mental disorders. Consequently an analysis of genes in the VCFS deleted region is relevant. In addition to chromosome 22, several other chromosomal loci have been linked to both SZ and BPD and a common gene may increase susceptibility to both conditions in subgroups of patients (reviewed in Berrittini).
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SNAP29 is expressed ubiquitously and its role in transmitter release has not yet been established. However, there is a report that SNAP-29 binds syntaxin 1A and inhibits synaptic transmission in superior cervical ganglion neurons. 48 Considering the model presented above, its location in the VCFS deleted region, as well as its close proximity to markers mapped in both BPD and SZ, we viewed SNAP29 as a feasible candidate gene for chromosome 22q11-linked psychiatric disorders, and, consequently, SNAP29 exons and intronexon junctions, and the promoter region were screened for possible functional SNPs. Four SNPs were found in the screening, none of which were coding variants. However, there was a moderately significant difference in the allele and genotype distribution of one promoter SNP, which occurs in a core recognition sequence for several transcription factors, in schizophrenics compared with controls.
Methods

Subjects
Patients with schizophrenia were recruited from the Bronx Psychiatric Center, Long Island Jewish Hillside Hospital and Rockland State Hospital. The diagnosis was established by RDC criteria using SCID (LIJ) or clinical interview (Rockland State Hospital, Bronx Psychiatric Center) using DSM-IV criteria. Patients with BPD were diagnosed on the basis of either a SADS-L interview or by unstructured clinical interview modified from SADS-L that yielded diagnostic information enabling the diagnosis of BPD using RDC criteria. The patients were recruited from clinics and private practices affiliated with the Albert Einstein College of Medicine. Forty-three subjects were unrelated patients with BPI disorder obtained from the Coriell Institute in conjunction with the The National Institutes of Mental Health Bipolar Genetics Initiative. Patients signed an informed consent approved by the local Committee on Clinical Investigation. Control subjects were obtained from students, and hospital, medical school, and clinic staff; anonymous DNA samples obtained from liver biopsies, and anonymous blood donors. No formal testing procedure was used to screen controls for underlying psychiatric illness. All patients and controls were Caucasian. The mean ages for the bipolar, control and schizophrenic groups were 42.1 ± 11.3, 43.0 ± 16.7 and 43.0 ± 8.5 respectively (mean ± standard deviation). There were 60 females and 47 males in the control group, 68 females and 56 males in the bipolar group (36 with BPII and 88 with BPI), and 71 males and 34 females in the schizophrenic group. There are small differences in the number of samples genotyped for each marker since every DNA sample did not give a readable genotype for each SNP. We attribute this to the difficulty in amplifying DNA with a very high GC content (see next section).
Mutation detection and genotyping DNA was extracted from whole blood or buccal smears using a Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN, USA) or by standard phenol extraction methods. Overlapping amplified DNA fragments from a region of DNA starting at position 93841 (963 nucleotides upstream from the translation start site) of the SNAP29 gene (GenBank accession number AC002470) and terminating at position 123 598 were scanned for mutations using a modification of the single strand conformation polymorphism (SSCP) analysis procedure originally described by Orita et al. 49 Sequence information for synthesizing primers and mapping intron-exon borders was obtained using GenBank accession numbers AC002470 and AF115436. To optimize allele detection, primers were chosen so that PCR products would be relatively small, approximately 200-250 nucleotide base pairs in length. The exception is the 380 nucleotide PCR fragment generated using the 1AF/1BR primer set which was digested with Dde1 to generate two smaller fragments appropriate for SSCP. SSCP analysis of the digested amplicon revealed the presence of band shifts that were found, on subsequent DNA sequence analysis, to be caused by the presence of two Dde1 restriction fragment length polymorphisms (RFLPs). The primers used for PCR amplification and sequencing are listed in Table 1 .
PCR was performed in a 20-l reaction volume containing 50 ng genomic DNA, a mixture of all four nucleotides (final concentration 0.2 mM for each), 1 × reaction buffer, 20 picomoles of each primer and 1.25 U taq polymerase. The PCRx enhancer system (Gibco-BRL, Gaithersburg, MD, USA) was used to amplify fragments from the SNAP29 promoter region and the 5Ј untranslated region since these regions are extremely GC-rich. We used 1 l of enhancer buffer in a 20-l reaction for all primer pairs except for 1AF/2BR and pro5F/pro5R, for which 2 l and 3 l were used, respectively. All denaturation steps were at 94°C except for the 1AF/1BR PCR reaction for which a 98°C denaturation temperature was used.
For mutation screening by SSCP, 5 l of PCR product was denatured for 5 min at 95°C with 20 l of denaturing mix (90% formamide, 0.5 × TBE, 0.02 N NaOH, Primer pairs used for generating PCR products for SSCP analysis. The sequence numbers correspond to the start of the forward primer (F) and the end of reverse primer (R) (GenBank accession number AC002470). Annealing temperatures used for PCR reactions are shown. PCR conditions including amount of PCRx enhancer system buffer used are described in Methods.
Molecular Psychiatry 0.1% xylene cyanol, 0.1% bromocresol purple) and then quenched on ice. The samples were loaded onto 4-20% non-denaturing acrylamide minigels (one millimeter thick) containing 4% glycerol (Novex, San Diego, CA, USA) in 1.25 × TBE buffer. A control sample containing non-denatured DNA was used to identify bands that corresponded to annealed double stranded DNA. The samples were subjected to electrophoresis at 200 V until the xylene cyanol dye reached the bottom of the gel. In order to maximize allele detection, two different temperatures were used, 4°C and 25°C. The temperature of the gel was maintained using a circulating, temperature-controlled water bath. Following electrophoresis, the gel was stained with SYBR II dye according to the manufacturer's instructions (Novex) and photographed under UV light. For the pro1 SNP, genotyping was accomplished using a labeled product generated by reducing the dCTP final concentration from 200 M to 100 M and adding 0.25 l 32 P-dCTP (3000 Ci mMol −1 ). The samples were denatured and subjected to electrophoresis through long 5% acryla-mide gels containing 5% glycerol in 0.5 × TBE buffer until the xylene cyanol tracking dye migrated approximately 35-40 cm. Gels were dried and exposed to Xray film at −70°C with intensifying screens for approximately 18 h. DNA samples homoygous for the two alleles were used as controls.
RFLP analysis was used to genotype two SNPs in the 5Ј untranslated region/exon 1 region amplified with the 1AF/1BR primers. The 380-nucleotide PCR fragment generated with these primers was digested with Dde1 to genotype the 56T/C and 92G/A SNPs. The combination of the 56C allele and 92A allele resulted in restriction fragments of 108bp+4sn (sn is the abbreviation for single nucleotide; an overhang of 4 single nucleotide bases is generated by Dde1 digested DNA) and 269bp+4sn; the 56T allele and 92A allele combination resulted in fragments of 108bp+4sn, 174bp+8sn and 92bp+4sn; the 56T and 92G allele combination resulted in fragments of 108bp+4sn, 141bp+8sn, 92bp+4sn, 30bp+8sn. No bands corresponding to the combination of 56C and 92G (predicted to give 108bp+4sn, 141bp+8sn, 135+4sn) were observed in our samples.
An SNP identified with the pro5F/pro5R primers creates an RFLP for the restriction enzyme Nae1. In order to analyze this SNP, the following assay was developed. A 513-bp DNA fragment was generated with primers pro4F and pro6R. Following 30 cycles of amplification, 5 units of Nae1 were added directly to the PCR reaction for 3 h at 37°C. Four l of 6 × loading buffer were added and the sample was electrophoresed through a 1.2% agarose minigel containing ethidium bromide. The DNA bands were visualized and photographed on a UV-lightbox. The wild-type allele results in bands 337 and 176 bp in length. As a result of the Nae1 RFLP, the 337-bp band is divided into bands 315 and 18 bp in length. The 18-bp fragment is not visualized under the electrophoresis conditions used.
All genotypes were scored independently by two investigators (TS and HL). When there were discrepancies, the gels were reviewed together and if no agreement could be reached, the analysis was repeated. There were no instances in which a sample had to be rejected on the basis of an unresolved discrepancy.
DNA sequence DNA samples with SSCA band shifts were subjected to DNA sequence analysis. This was performed on purified PCR templates using fluorescent-labelled dideoxy sequencing and an Applied Biosystems model 377 sequencer. Prior to sequencing, the PCR products were purified using a commercially available column to separate unused primers and nucleotides from the PCR reaction (Qiagen, Valencia, CA, USA). All polymorphisms were confirmed by sequencing the opposite strand.
Computer analysis
The BLAST network service at the National Center for Biotechnology Information (NCBI) was used to compare DNA sequences. Putative promoter regions were analyzed using the programs Matinspector V2.2 50 and TFMATRIX (http://pdap 1.trc.rwcp.or.jp/research/db/ TFSEARCH.html).
Statistical analysis
The association to the SNAP29 SNPs was tested using the Pearson 2 test (2 × 2 table for allele frequency) and a 2 test for independence (3 × 2 table for genotypes). The P-values were 2-tailed. A StatXact-3 statistical program was used to compute the 2 values. Hardy-Weinberg equilibrium calculations were performed using a goodness-of-fit test.
Results
PCR fragments derived from the exons, intron-exon junctions, and promoter of the SNAP29 gene were screened for polymorphisms by SSCP using 20 samples of DNA from patients with BPD and 20 with SZ. The coding region contains five exons encoding a 258-amino acid protein. No band shifts were detected in exons 2-5. In the analysis of exon 1, SNPs (56T/C and 92G/A) were found 56 and 92 base pairs downstream of the transcription start site (the transcription start site at position 94 731 GenBank accession number AC002470 is designated as position 1 in this study) (Figure 1a) . The 56T/C SNP occurs 19 nucleotides upstream of the translation start site, in the 5Ј untranslated region and is probably not functionally significant, although it does occur near a putative polypyrimidine tract (ctcctccttctgtttcccagacC/T). The 92G/A SNP results in a silent mutation at codon 6 (AAG → AAA).
The frequency of 56T and 56C in controls was 0.47 and 0.53 respectively, and the frequency of 92G and 92A was the same, 0.47 and 0.53 respectively ( Table  2 ). The two SNPs are nearly in complete linkage disequilibrium; the 56T and 92G alleles are found together on 99% of chromosomes analyzed. No significant difference was found in the allele frequency or genotype distribution in patients with BPD (92G/A: alleles, control vs BP; Since no coding variants were found, the SNAP29 5Ј-flanking region was also screened for polymorphisms. Although the promoter region has not yet been mapped by molecular analysis, a computer analysis identified consensus sequences for transcription factors including SP1, USF, GATA1, GATA2, and GATA3 among others, in a region several hundred nucleotides upstream of the transcription start site. Similar to a number of 'housekeeping genes', a classic TATA consensus sequence was not found in the SNAP-29 promoter region.
Only two SNPs were identified in the 942 nucleo- Number of subjects in each category followed by percentage in parenthesis. Abbreviations are control (CONT), bipolar disorder (BPD) and schizophrenia (SZ). 56T → C allele distribution (1 df) and genotype distribution (2 df) respectively: CONT vs SZ, DNA sequence analysis of the pro1F/pro1R SNP revealed an A → G transition at position 93 881, 922 nucleotides upstream of the translation start site, 849 nucleotides upstream from the transcription start site (−849G/A). The −849A allele results in the tetranucleotide GGAA which forms the core binding site for the ets and NRF-2 families of transcription factors, 51, 52 whereas −849G results in the tetranucleotide GGGA, the core binding site of the IK2 transcription factor 53, 54 ( Figure 1b) . Despite their close proximity, the −849 SNP is not in complete linkage disequilibrium with the exon 1 SNPs. Ninety-three percent of chromosomes with the −849G allele were linked to the 56C allele and 7% were linked to the 56T allele.
The frequency of alleles A and G are 0.51 and 0.49 respectively in control populations (Table 3) . A similar frequency was found in patients with BP (0.49 and 0.51) and there was no significant difference in the allele distribution between controls and patients with BPD (P = 0.70). A slight difference was detected in the genotype distribution that just fell short of statistical significance ( 2 = 5.57, 2 df, P = 0.06). This was due to a relative increase in the number of bipolar patients who were found to be homozygous for either of the two alleles, and a relative decrease in heterozygotes. Despite the similarity in allele frequencies, 31% of bipolar patients are homozygous for −849G and 28% for −849A compared with 21% and 22% respectively in controls. A comparison of homozygotes for the −849G allele and all other genotypes showed a statistical trend when bipolar patients were compared with controls ( 2 = 2.75, P = 0.098). There was no significant deviation from Hardy-Weinberg equililibrium in the genotype distribution of controls (P = 0.136) and a trend towards disquilibrium was found in patients with BPD (P = 0.06).
A moderately significant difference in the allele frequency and genotype distribution was found when patients with SZ were compared with controls (allele frequency: 2 = 5.57, 1 df, P = 0.018; genotypes: 2 = 9.49, 2 df, P = 0.009, odds ratio = 1.59, 95% CI = 1.08-2.34). The results overestimate the degree of significance when corrected for multiple testing. A 0.05 level of significance would be reduced by a factor of 16 (P = 0.003) for 16 tests (bipolar and schizophrenia for 4 SNPs, both allele and genotypes analyzed). Only 7.6% of SZ patients were homozygous for 849A compared with 22.4% of controls and 28.6% of patients with BPD. The ratio of homozygotes for −849G to homozygotes for −849A was 0.92 for controls, 1.07 for BPD and 3.75 for SZ.
In addition to the moderately significant differences between controls and patients with SZ, the genotype distribution for the −849 SNP in schizophrenics showed a significant departure from Hardy-Weinberg equilibrium ( 2 = 11.77, P = 0.0006). These data suggest that either a decrease in homozygosity for the −849A allele, an increase in homozygosity for −849G, or another mutation in or near the SNAP29 gene in linkage disequilibrium with the −849 promoter SNP, increases the risk for SZ.
Discussion
Approximately 80% of patients with VCFS have a microdeletion on 22q11. Of these, approximately 90% have a 3-mb deletion that includes the SNAP29 gene. 36, 37, 55 The remainder have either a 1.5-mb deletion or translocations with breakpoints within the 1.5-mb region that do not involve SNAP29. Since psychiatric problems occur in a subset of patients with VCFS, a plausible hypothesis is that there is a relationship between deletion size and the development of psychiatric illness. So far, however, no specific relationship has been established. In our previous study of VCFS patients with psychiatric illness, 22 had the 3-mb deletion, one had the 1.5-mb deletion, and two had no detectable deletion 55, 56 (B Morrow, Albert Einstein College of Medicine, personal communication). The three patients without the 3-mb deletion were diagnosed with either BPII or ADD. Every patient diagnosed with either BPI or schizoaffective disorder in our cohort was found to have the 3-mb deletion. However, we are aware of at least one VCFS patient diagnosed with schizophrenia by another group who has the 1.5-mb deletion (B Morrow, personal communication).
The COMT and proline dehydrogenase genes are both found in the 1.5-mb deleted region and have been considered as candidates for the psychiatric manifestations of VCFS, and in the case of COMT, for 22q-linked psychiatric disorders occurring in the general population. A common functional variant of COMT caused by a missense mutation at codon 158 may be associated with ultra-ultra rapid cycling in patients with BPD from the general population and in VCFS patients diagnosed with BPD, and increased aggression in patients with SZ. [57] [58] [59] [60] [61] [62] However, most studies indicate that COMT is not directly involved in the development of the core symptom complex of either BPD or SZ, and does not appear to explain all of the psychiatric manifestations of VCFS. 56, [63] [64] [65] [66] A family based linkage disequilibrium mapping study published recently using markers in COMT and an adjacent gene, ARVCF, provided evidence for increased disease susceptibility at that locus in SZ. 46 Gogos et al 67 found a mutation in the murine proline dehydrogenase gene that results in an increase in proline levels and a sensorimotor gating abnormality. Since patients with SZ show the same type of abnormality, the proline dehydrogenase gene has to be viewed as a credible candidate gene for 22q11-linked SZ and the psychiatric manifestations of VCFS. So far, no published reports of allelic variants in humans have appeared.
Although, deletion of SNAP29 does not appear to be essential for the development of all psychiatric problems in patients with VCFS, it could still be a contributing factor to the mental health of a subgroup of VCFS patients since it is deleted in approximately 70% of cases. It is also conceivable that SNAP29 expression could be affected in patients with the 1.5-mb deletion through a distal, cis-acting mechanism; SNAP29 is approximately 300 kb from the telomeric border of the 1.5-mb deletion. However, correlating mental illness with deletion size in VCFS may be complicated by other diagnostic issues in these patients. For example, nearly all VCFS patients have a learning disability and an increase in the prevalence of SZ has been observed in individuals with learning disabilities. 68, 69 Thus, deletion of a gene or genes in the 1.5-mb region causing the learning disability in VCFS may predispose a subset of patients to SZ if they also inherit a susceptibility locus or loci elsewhere on 22q, or other chromosomes.
Whether or not SNAP29 is involved in the psychiatric manifestations of VCFS, our data suggest that it could be a factor in the development of SZ in the general population. A moderately significant difference in the allele and genotype distribution was found to the −849 promoter SNP in patients compared with controls. However, our significant results should be tempered by the possible overinflation due to multiple testing. Furthermore, population stratification could be a factor since a heterogenous population of Caucasian subjects was used in both control and patient populations and the SZ patients were not matched for gender.
One finding that provides some support for an association is that a significant deviation (P = 0.0006) from a Hardy-Weinberg equilibrium in the −849 genotype distribution was detected. Since the presence of Hardy-Weinberg disequilibrium can be used to map a disease locus, 70 the notion that the −849 promoter SNP (or a nearby functional alteration), is involved in the pathogenesis of SZ is strengthened. However, deviation from Hardy-Weinberg equilibrium may also be due to ascertainment bias.
Although the functional role of the −849 SNP is not known, it is possible that it may influence the binding of transcription factors. The −849A allele is part of the tetranucleotide GGAA which is the conserved core recognition sequence for the elk/ets and NRF-2 families of transcription factors, while the −849G allele is part of the tetranucleotide GGGA core recognized by IK2, a member of the Icaros family of zinc finger transcription factors (Figure 1) . Overall, there is a 9/10 nucleotide match for an ets consensus sequence with −849A.
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Members of the ets and elk families are expressed throughout the brain. 71 NRF-2 is a transcriptional activator of cytochromes and other respiratory enzymes. 51 Ikaros transcription factors are involved in lymphoid development in adults and during fetal development, and are expressed in the developing brain. 53, 54 Some members of the Ikaros family act as transcriptional repressors. There is an 8/11 base pair match for a consensus IK2 binding site, defined by in vitro selection, surrounding and including the −849G allele. Functional analysis of the −849 SNP, as well as precise mapping and mutation screening of the entire SNAP29 promoter region are necessary.
Finally, the results of this and our previous study on SYBL1 suggest that genes involved in synaptic vesicle function that map to regions that contain BPD and SZ susceptibility genes, such as RAB36, synapsin III, and synaptogyrin 1 (22q11-13), syntaxin 7 (6q21), synaptophysin (Xp11), and SYNJ1 (21q22), should be considered as very plausible candidate genes for analysis in SZ and BPD.
